Correction: Sublingual Ketamine

Correction

In the letter “Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?” by Jennifer Swainson, MD, and Atul Khullar, MD, MSc, published in the January/February 2020 issue (J Clin Psychiatry 2020;81[1]:19lr13146), conflict of interest information has been corrected to show that Dr Swainson has been on advisory boards for, received speaker honoraria from, and provided consultancy services to Lundbeck, Otsuka, Sunovion, and Janssen, and Dr Khullar has been on advisory boards for, received speaker honoraria from, and provided consultancy services to Lundbeck, Otsuka, Sunovion, Janssen, Shire, Bausch, Takeda, and Eisai.